ELUT
NASDAQElutia Inc.
News · 26 weeks38-80%
2026-04-192026-10-11
Mix1790d
- SEC Filings6(35%)
- Other6(35%)
- Insider3(18%)
- Earnings2(12%)
Latest news
25 items- PRElutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestitureThe Company is now fully funded through the first year of the expected NXT-41x launch and into 2029 GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific Corporation (NYSE:BSX). The payment was m
- INSIDERCHIEF SCIENTIFIC OFFICER Williams Michelle Leroux converted options into 12,500 shares and covered exercise/tax liability with 4,269 shares, increasing direct ownership by 7% to 126,283 units (SEC Form 4) (tax liability)4 - ELUTIA INC. (0001708527) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Ferguson Matthew converted options into 12,500 shares and covered exercise/tax liability with 4,486 shares, increasing direct ownership by 2% to 489,903 units (SEC Form 4) to cover withholding tax4 - ELUTIA INC. (0001708527) (Issuer)
- INSIDERPRESIDENT AND CEO Mills C Randal converted options into 27,083 shares and covered exercise/tax liability with 9,718 shares, increasing direct ownership by 4% to 464,395 units (SEC Form 4) (tax liability)4 - ELUTIA INC. (0001708527) (Issuer)
- PRElutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15thGAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer; Dr. Michelle Williams, Chief Scientific Officer; and Matthew Ferguson, Chief Financial Officer, will present and host one-on-one meetings with investors at the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York City on September 15–16, 2026. During the presentation, management will discuss how Elutia is working to address post-surgical infection in plastic and reconstructive surgeries—one of the most significant challe
- PRElutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment ConferenceGAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, Matthew Ferguson, Chief Financial Officer, and Dr. Michelle Williams, Chief Scientific Officer, will participate in two upcoming investor conferences. Lake Street Capital Markets 10th Annual Big Ideas Growth ConferenceElutia will host one-on-one meetings with investors at the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference at the Metropolitan Club in New York City on September 10, 2026. To schedule a one-on-one meeting, institutional investors may con
- SECElutia Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ELUTIA INC. (0001708527) (Filer)
- PRCellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.ROSWELL, Ga., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cellution Biologics Inc. ("Cellution Biologics" or the "Company"), a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, today announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc. (NASDAQ:ELUT). The acquisition marks Cellution Biologics’ entry into the U.S. reconstructive surgery market, adding a new surgical category to its existing portfolio across wound care, ocular repair and other surgical applications. SimpliDerm is an established human acellular dermal matrix with a proven commercial presence in
- PRElutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial LaunchDeal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 monthsDivestiture further concentrates Elutia’s attention and resources on the development and commercialization of NXT-41x NXT-41x is an antibiotic-eluting biomatrix designed to address post-operative infection in the $1.5 billion U.S. plastic and reconstructive surgery market NXT-41x clearance expected in the first half of 2027 GAITHERSBURG, Md., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced it completed the sale of its SimpliDerm® human acellular
- SECSEC Form S-8 filed by Elutia Inc.S-8 - ELUTIA INC. (0001708527) (Filer)
- SECSEC Form 10-Q filed by Elutia Inc.10-Q - ELUTIA INC. (0001708527) (Filer)
- SECElutia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ELUTIA INC. (0001708527) (Filer)
- PRElutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 ResultsFunded through launch: secured up to $26 million of capital without an equity offeringThe unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection riskThe demand is strong: 96% of surgeons surveyed are interested in adopting NXT-41x; 92% responded they would champion it at their hospital value analysis committeeOn track: NXT-41 FDA clearance decision expected in 4Q 2026; NXT-41x FDA clearance decision expected in 1H 2027 GAITHERSBURG, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today provided a business update and announced financial results for the se
- PRElutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market$10 million funded at closing; second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41xPreserves shareholder value by funding commercialization of Elutia's next-generation antibiotic-eluting biomatrix without an equity offeringNXT-41x targets the 15–20% post-operative infection rates in multiple complex plastic and reconstructive surgical procedures GAITHERSBURG, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced a $15 million growth capital financing agreement with Avenue Capital Group ("Avenue Capital"). The transaction strengthens Elutia’s balance sheet and funds
- SECElutia Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - ELUTIA INC. (0001708527) (Filer)
- PRElutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026GAITHERSBURG, Md., July 31, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2026 financial results after market close on Thursday, August 13, 2026. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the
- SECElutia Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ELUTIA INC. (0001708527) (Filer)
- PRElutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x LaunchTransaction provides $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 monthsProceeds provide additional non-dilutive capital to advance NXT-41x toward anticipated clearance and targeted commercial launch in 2027Divestiture sharpens Elutia’s focus on NXT-41x and the $1.5 billion plastic and reconstructive surgery opportunity GAITHERSBURG, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the signing of a definitive agreement to sell its SimpliDerm® human acellular dermal matrix business to Cellution Biologi
- INSIDERPRESIDENT AND CEO Mills C Randal converted options into 22,473 shares and covered exercise/tax liability with 8,064 shares, increasing direct ownership by 3% to 441,180 units (SEC Form 4) to cover taxes4 - ELUTIA INC. (0001708527) (Issuer)
- SECElutia Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ELUTIA INC. (0001708527) (Filer)
- INSIDERSEC Form 4 filed by Director Rakin Kevin4 - ELUTIA INC. (0001708527) (Issuer)
- INSIDERSEC Form 4 filed by Director Colpman David4 - ELUTIA INC. (0001708527) (Issuer)
- INSIDERSEC Form 4 filed by Director Makes Brigid4 - ELUTIA INC. (0001708527) (Issuer)
- INSIDERSEC Form 4 filed by Director Neels Guido J4 - ELUTIA INC. (0001708527) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Williams Michelle Leroux converted options into 12,500 shares and covered exercise/tax liability with 4,269 shares, increasing direct ownership by 7% to 118,052 units (SEC Form 4) (tax liability)4 - ELUTIA INC. (0001708527) (Issuer)
ELUT FAQ
5 questionsWhere does ELUT stock trade?
Elutia Inc. (ELUT) is listed on NASDAQ.What sector and industry is ELUT in?
Elutia Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Elutia Inc. go public?
Elutia Inc. (ELUT) completed its IPO in 2020.What companies are similar to ELUT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ELUT side-by-side with any of them on Quantisnow.How can I track ELUT on Quantisnow?
Quantisnow aggregates Elutia Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ELUT to receive live email and push alerts on every new disclosure.